Abstract:Chronic inflammation is a key player in metabolic dysfunction-associated fatty liver disease (MAFLD) progression. Necroptosis, an inflammatory cell death pathway, is elevated in MAFLD patients and mouse models, yet its role is unclear due to the diverse mouse models and inhibition strategies. In our study, we inhibited necroptosis by targeting mixed lineage kinase domain-like pseudokinase (MLKL), the terminal effector of necroptosis, in a high-fat, high-fructose, high-cholesterol (HFHFrHC) mouse model of diet-induced MAFLD. Despite the HFHFrHC diet upregulating MLKL (2.5-fold), WT mice livers showed no increase in necroptosis markers or associated proinflammatory cytokines. Surprisingly, Mlkl−/− mice experienced exacerbated liver inflammation without protection from diet-induced liver damage, steatosis, or fibrosis. In contrast, Mlkl+/− mice showed a significant reduction in these parameters that was associated with elevated Pparα and Pparγ levels. Both Mlkl−/− and Mlkl+/− mice on the HFHFrHC diet resisted diet-induced obesity, attributed to the increased beiging, enhanced oxygen consumption, and energy expenditure due to adipose tissue, and exhibited improved insulin sensitivity. These findings highlight the tissue-specific effects of MLKL on the liver and adipose tissue, and they suggest a dose-dependent effect of MLKL on liver pathology.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to explore the role of mixed - lineage kinase domain - like pseudokinase (MLKL), as a key effector molecule in the necroptosis pathway, in obesity - driven metabolic - associated fatty liver disease (MAFLD) and insulin sensitivity. Specifically, the study aims to clarify how MLKL deficiency (achieved by using Mlkl−/− and Mlkl+/− mouse models) affects obesity - related liver injury, fibrosis and metabolic outcomes induced by a high - fat, high - fructose, high - cholesterol (HFHFrHC) diet. ### Research Background and Problems 1. **Prevalence and Pathological Mechanisms of MAFLD** - MAFLD is a liver disease closely related to obesity, type 2 diabetes and insulin resistance, characterized by the progression from hepatic steatosis to metabolic - dysfunction - associated steatohepatitis (MASH). - Hepatocyte death (especially programmed necrosis) plays a key role in the pathological process of MAFLD, leading to inflammation and fibrosis. 2. **The Role of MLKL in Necrosis** - MLKL is the terminal effector molecule in the programmed necrosis pathway. Its activation leads to an increase in cell membrane permeability and the release of damage - associated molecular patterns (DAMPs), thus triggering an inflammatory response. - Previous studies have shown that inhibiting MLKL can reduce liver inflammation and fibrosis, but the results in different models are inconsistent. 3. **Research Objectives** - **Primary Objective**: To explore the role of MLKL in obesity - driven MAFLD, especially its impact on liver injury, fibrosis and metabolic outcomes. - **Specific Questions**: To evaluate the liver pathological changes and metabolic manifestations of mice with complete MLKL deletion (Mlkl−/−) and partial deletion (Mlkl+/−) under an HFHFrHC diet, in order to reveal the tissue - specific effects of MLKL in these processes. ### Research Methods - Use wild - type (WT), Mlkl−/− and Mlkl+/− male mice and feed them an HFHFrHC diet for 6 months. - Compare the body weight, fat content, liver weight, lipid deposition, inflammation markers, insulin sensitivity and other indicators among the groups of mice. - Through transcriptomics and proteomics analysis, explore the effects of MLKL deficiency or reduction on fatty acid metabolism, oxidative stress response and the expression of inflammatory factors. ### Main Findings - Mlkl−/− and Mlkl+/− mice show resistance to diet - induced obesity, manifested as less weight gain and reduced fat accumulation. - Mlkl+/− mice show a protective effect against liver injury and steatosis under an HFHFrHC diet, while Mlkl−/− mice do not show this protection. - Partial deletion of MLKL (Mlkl+/−) improves insulin sensitivity and reduces liver fibrosis, while complete deletion (Mlkl−/−) does not show these effects. - In adipose tissue, MLKL deletion or reduction promotes beiging, enhancing oxygen consumption and energy expenditure. ### Conclusions This study reveals the complex role of MLKL in obesity - driven MAFLD, especially the tissue - specific effects in the liver and adipose tissue. These findings provide new insights into understanding the role of MLKL in metabolic diseases and may provide potential targets for the development of new therapies for MAFLD.

Insights from a High-Fat, High-Fructose, High-Cholesterol Diet Mouse Model

Non-Necroptotic Roles of MLKL in Diet-Induced Obesity, Liver Pathology, and Insulin Sensitivity: Insights from a High Fat, High Fructose, High Cholesterol Diet Mouse Model

Divergent roles of RIPK3 and MLKL in high-fat diet-induced obesity and MAFLD in mice

Role of necroptosis in chronic hepatic inflammation and fibrosis in a mouse model of increased oxidative stress

Receptor-interacting protein 1 and 3 kinase activity are required for high-fat diet induced liver injury in mice

Differential role of MLKL in alcohol-associated and non–alcohol-associated fatty liver diseases in mice and humans

The hepatocyte IKK:NF-κB axis promotes liver steatosis by stimulating de novo lipogenesis and cholesterol synthesis

Insights from a high-fat diet fed mouse model with a humanized liver.

Steatosis, inflammasome upregulation, and fibrosis are attenuated in miR-155 deficient mice in a high fat-cholesterol-sugar diet-induced model of NASH

Macrophage Scavenger Receptor 1 mediates lipid-induced inflammation in non-alcoholic fatty liver disease

Mice Deficient in the IL-1β Activation Genes Prtn3, Elane, and Casp1 Are Protected Against the Development of Obesity-Induced NAFLD

Receptor-Interacting Serine/Threonine-Protein Kinase 3 (Ripk3)-Mixed Lineage Kinase Domain-Like Protein (Mlkl)-Mediated Necroptosis Contributes to Ischemia-Reperfusion Injury of Steatotic Livers

Long‐term hypercaloric diet exacerbates metabolic liver disease in PNPLA3 I148M animals

Mutation in the distal NPxY motif of LRP1 alleviates dietary cholesterol-induced dyslipidemia and tissue inflammation

Role of MCP-1 on inflammatory processes and metabolic dysfunction following high-fat feedings in the FVB/N strain

Longitudinal Analysis of Mitochondrial Function in a Choline-Deficient L-Amino Acid-Defined High-Fat Diet-Induced Metabolic Dysfunction-Associated Steatohepatitis Mouse Model

Dietary Factors Alter Hepatic Innate Immune System in Mice with Nonalcoholic Fatty Liver Disease

Necroptosis contributes to chronic inflammation and fibrosis in aging liver

Ferroptosis inhibitor liproxstatin-1 alleviates metabolic dysfunction-associated fatty liver disease in mice: potential involvement of PANoptosis

Prolonged high-fat-diet feeding promotes non-alcoholic fatty liver disease and alters gut microbiota in mice

Impaired Mitophagy Triggers NLRP3 Inflammasome Activation During the Progression from Nonalcoholic Fatty Liver to Nonalcoholic Steatohepatitis